REMEGEN CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.5 HKD | +0.83% |
|
+10.11% | -18.56% |
ETFs positioned on RemeGen Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 4 M€ | -27.92% | ||
| 0.12% | 2 M€ | -14.14% | ||
| 0.00% | 7 M€ | +1.16% | - | |
| 0.00% | 34 M€ | +2.22% | - |
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
28
CNY
Average target price
39.93
CNY
Spread / Average Target
+42.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.56% | 3.42B | |
| -3.05% | 103B | |
| +0.72% | 95.71B | |
| +0.52% | 22.02B | |
| -16.87% | 20.9B | |
| -9.42% | 17.85B | |
| -42.83% | 16.21B | |
| -16.33% | 15.52B | |
| +5.20% | 13.86B | |
| +31.49% | 12.04B |
- Stock Market
- Equities
- 9995 Stock
- Funds and ETFs RemeGen Co., Ltd.
